We are currently completing a Phase 1b clinical trial with OMP-305B83 (navicixizumab) in combination with paclitaxel in patients with heavily pre-treated platinum-resistant ovarian cancer. Ovarian cancer remains a deadly malignancy because most patients develop recurrent disease that is resistant to chemotherapy, including platinum.
OMP-305B83 (navicixizumab) is an anti-DLL4/VEGF bispecific antibody targeting both DLL4 in the Notch cancer stem cell pathway and vascular endothelial growth factor (VEGF). This antibody is expected to have anti-angiogenic plus anti-cancer stem cell activity. In a Phase 1a clinical trial in 66 patients, OMP-305B83 (navicixizumab) demonstrated single-agent anti-tumor activity and was safe enough to be administered on a continuous basis.
Information on navicixizumab clinical trials is available here: Navicixizumab ClinicalTrials.gov.
Public presentations of studies on navicixizumab include:
- A Phase 1b Study of Navicixizumab & Weekly Paclitaxel in Heavily Pre-Treated Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer - ESMO 2018
- A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors - Investigational New Drugs, Sep 19 2018
- A First-in-Man Phase 1a Study of the Bispecific Anti-DLL4/Anti-VEGF Antibody OMP-305B83 in Patients with Previously Treated Solid Tumors - EORTC-NCI-AACR 2016
- Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses - SITC 2015
- Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency - AACR-NCI-EORTC 2015